The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Loans made | 0 |
| Net cash used in investing activities | 0 |
| Equity in net loss of equity method investees | 0 |
| Impairment loss, newstem | 0 |
| Bad debt expense | 0 |
| Loss on derivative instrument | 0 |
| Accrued expenses | 0 |
| Accretion of discount on note payable | 60,417 |
| Gain on disposal of equity method investment | 1,171,760 |
| Accrued interest added to short term notes payable | 36,830 |
| Accrued interest added to long-term notes payable | 136,647 |
| Accrued interest added to bridge loan payable | 9,990 |
| Accrued interest added to convertible debt | 10,168 |
| Stock-based compensation | 8,838 |
| Accounts receivable, administrative fees | -10,500 |
| Prepaid expenses | 181 |
| Accounts payable | 48,060 |
| Net income (loss) | 2,379,882 |
| Relief of indebtedness income | -1,697,024 |
| Net cash used in operating activities | -167,633 |
| Proceeds from convertible debt | 0 |
| Proceeds from note payable, current | 0 |
| Proceeds from bridge loan payable | 161,867 |
| Net cash provided by financing activities | 161,867 |
| Net change in cash | -5,766 |
| Net change in cash | -5,766 |
| Cash at the beginning of the year | 6,099 |
| Cash at the end of the year | 333 |
NovelStem International Corp. (NSTM)
NovelStem International Corp. (NSTM)